NCT02374385View on ClinicalTrials.gov

Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

June 30, 2015

Conditions
Ebola Viruses
Interventions
BIOLOGICAL

BPSC-1001 (VSVΔG-ZEBOV)

Ebola vaccine candidate

OTHER

Placebo

Normal saline

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

NewLink Genetics Corporation

INDUSTRY

lead

Dalhousie University

OTHER

NCT02374385 - Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine | Biotech Hunter | Biotech Hunter